Integrating PIK3CA Testing into Clinical Practice for Advanced HR+/HER2- Breast Cancer: An Expert Consensus (Review)
https://t.co/B4MiL5AkVq
PIK3CA 🧬mutations are key actionable biomarkers in advanced HR+/HER2− #BreastCancer , guiding use of PI3K inhibitors like alpelisib and inavolisib. Next-generation sequencing is preferred to detect canonical and non-canonical variants. Tumor tissue is the primary testing source, with liquid biopsy🩸 as an alternative.
Activating mutations in tissue or plasma identify eligible patients. Consensus recommendations standardize testing, reporting, and clinical integration to improve care and align with current evidence.
@curijoey@BianchiniGP@UmbertoMalapel1@LGerratana
@NicolaFuscoMD
@dariodebiase@CarmineDeA1@puglisi_fabio@grazia_arpino@delmastro_lucia@ALEDIGNUS12@OncoAlert 🚨
Pratica clinica, confronto, visione. 🩺 È in corso oggi Evolving Therapies, una giornata di confronto concreto su una delle sfide più complesse in oncologia mammaria.
Il #TNBC è al centro di una discussione viva e dinamica, orientata anche al futuro ma con un impatto immediato sulla gestione quotidiana dei pazienti.
Il dialogo tra esperti si conferma fondamentale: è qui che la complessità trova risposte concrete.
Grande partecipazione e coinvolgimento anche nei momenti interattivi – escape room clinica e decision game – pensati per tradurre la conoscenza in pratica clinica reale, dove ogni esperienza contribuisce a ridefinire il percorso di cura.
Un ringraziamento speciale ai Responsabili Scientifici, Carmine De Angelis e Matteo Lambertini, per aver guidato l’ideazione di questa giornata, e a tutta la Faculty per aver arricchito questa giornata di formazione.
Grazie anche a Gilead per il supporto non condizionante.
@CarmineDeA1@matteolambe@BlondeauxEva, @DottBotticelliA, @Roberta27585687, @BenedettaConte5, @CarmenCriscit, @vitti10, @LGerratana, @ArmandOrlandi, @marti_pagliuca, @MariaVitaSano1, @angela_toss
Out in @eClinicalMed a network M-A evaluating treatment strategies after PD on CDK4/6i in HR+/HER2− mBC
Results support biomarker-driven algorithm and are relevant since head-to-head trials are unlikely to be conducted!
Congrats @RobertoBuonaiu3@CarmineDeA1 👏
@OncoAlert
🏅Optimal treatment sequencing after CDK4/6i + ET in HR+/HER2− MBC remains unclear due to lack of head-to-head trials 🤔
💻We conducted a systematic review & NMA to guide evidence-based decisions.
📰Read more: https://t.co/3QUFaERmUw
@OncoAlert@oncodaily@eClinicalMed
Riunione annuale GIM – Gruppo Italiano Mammella 📍 Domani 26 e 27 settembre a Bergamo.
Il #GIM è uno dei principali consorzi indipendenti per la ricerca sul carcinoma mammario, con oltre 150 centri e 500 sperimentatori coinvolti.
L’appuntamento annuale è un momento chiave per condividere risultati, aggiornarsi sui trial in corso e proporre nuovi studi, favorendo confronto e networking tra i maggiori esperti e giovani ricercatori del settore.
Responsabili Scientifici: Alberto Zambelli, Armando Santoro.
Comitato organizzatore: @arpino_grazia, @delmastro_lucia, Michelino De Laurentiis @MicheleDelauren, Sabino De Placido, Alessandra Fabi, @puglisi_fabio.
👉 Guarda il programma: https://t.co/jUNJ8F9uDA
#GIM #BreastCancer #Oncologia #ClinicalResearch
Biomarker analysis of the PACE trial in HR+/HER2– #metastatic#breastcancer after CDK4/6i:
‼️Baseline #CTC enumeration (≥5 CTCs) identifies patients with extended PFS from F+palbociclib (F+P) or F+P+avelumab vs fulvestrant (F) alone.
👉🧵 A thread
https://t.co/NRc31QGZWf
🧬 Patients with Stage IV aggressive disease had a higher prevalence of ESR1 and RB1 mutations, while no difference were observed for PIK3CA
🔹 ESR1 → 62.6% vs 41.3% (p=0.0008)
🔹 RB1 → 18.2% vs 4.8% (p=0.0031)
Mark your calendar for the International Inflammatory Breast Cancer Symposium!
🗓️ October 23, 2025
📍 Milan (Italy)
🌐 Join in person or online
Don’t miss this opportunity to connect with global IBC experts, share ideas, and advance research to improve patient outcomes.
Can #fragmentomics become a new monitoring #biomarker in metastatic breast cancer? 🔬
👉 Here we explore a mutation-agnostic, cost-effective approach tested in the MAGNETIC.1 trial—a longitudinal study of first-line HR+/HER2- MBC.
https://t.co/c7w9ir8iZ5
📢 Just out on @CROH our Italian Delphi consensus 🤝🏻on the evolving landscape of HR+/HER2- mBC (EVOLVE).
💊Resistance/sensitivity to CDK4/6i+ET
🧬Biomarkers
🔎Treatment algorithm
📃: https://t.co/LiAwSn8yDn
Proud to be part of this huge national effort.
Join UNC's Assistant Professor of Medicine @YAbdouMD on June 12 as she discusses racial inequities and HER2-Negative breast cancer. This group will fill up fast, so make sure you register today
https://t.co/MHgYtUr9jQ
#asco2025#bcsm#registertoday#GRASPPosters#GRASPatASCO
Join Mentor @JaniceTNBCmets on Wednesday, June 12 at 2:00 pm as she leads the discussion on Triple-Negative Breast Cancer and Antibody-Drug Conjugates (ACDs). These sessions fill up fast, so register today!
https://t.co/y1p22q00Uy
#asco#asco2025#bcsm#registertoday
Join GRASP Scientist Jennifer Sheng, M.D., as we discuss alcohol intake and health-related quality of life in breast cancer survivors, and alcohol intake. Join us on June 11 for a deeper into these topics and discuss Posters.
https://t.co/bNPPpyFIN5
#bcsm#GRASPPosters#alcohol